CARLSBAD, Calif., Dec. 14,
2023 /PRNewswire/ -- Ionis Pharmaceuticals, Inc.
(Nasdaq: IONS) today announced the appointment of Michael Yang, an experienced biopharmaceutical
executive, to the Ionis Board of Directors. Mr. Yang's appointment
expands the total number of Ionis Board members to 10.
Mr. Yang has more than 20 years of broad senior level leadership
experience in biotech, pharmaceutical and medical device companies,
where he launched new platforms, expanded global revenues and
diversified product lines. He most recently served as President,
Chief Executive Officer and Board member of ViaCyte, which was
acquired by Vertex in 2022. Prior to ViaCyte, Mr. Yang was
Executive Vice President and Chief Commercial Officer at Acadia
Pharmaceuticals from 2017 to 2021. During his tenure, Acadia
transformed the standard of care for patients with Parkinson's
disease psychosis. Prior to Acadia, Mr. Yang was President of
Janssen Biotech Inc., where he was responsible for building
Janssen's U.S. immunology business, generating more than
$8 billion in annual revenues.
"We are thrilled for Michael to join the Board as he adds deep
biopharmaceutical leadership experience, particularly important as
Ionis is poised to enter its next phase of growth," said
Joseph Loscalzo, M.D., Ph.D.,
chairman of the Ionis Board of Directors. "Michael's commercial
experience launching innovative medicines for patients in need will
be highly complementary to the strong science and business
expertise on the Board. We welcome his guidance and insights."
"I have known Michael for many years and have always appreciated
his wide-ranging experience in both rare and common diseases as
well as the strong patient focus he brings to our industry," said
Brett P. Monia, Ph.D., Ionis' chief
executive officer. "We are thrilled to have him as part of the
Board and the Ionis team looks forward to working with
him."
About Ionis Pharmaceuticals, Inc.
For more than 30 years, Ionis has been a leader in RNA-targeted
therapy, pioneering new markets and changing standards of care.
Ionis currently has four marketed medicines and a promising
late-stage pipeline highlighted by cardiovascular and neurological
franchises. Our scientific innovation began and continues with the
knowledge that sick people depend on us, which fuels our vision to
become the leader in genetic medicine, utilizing a multi-platform
approach to discover, develop and deliver life-transforming
therapies.
To learn more about Ionis visit www.ionispharma.com and
follow us on Twitter @ionispharma.
Ionis' Forward-looking Statements
This press release includes forward-looking statements regarding
Ionis' business, and the therapeutic and commercial potential of
Ionis' technologies, and other products in development. Any
statement describing Ionis' goals, expectations, financial or other
projections, intentions, or beliefs is a forward-looking statement
and should be considered an at-risk statement. Such statements are
subject to certain risks and uncertainties, including but not
limited to those related to our commercial products and the
medicines in our pipeline, and particularly those inherent in the
process of discovering, developing and commercializing medicines
that are safe and effective for use as human therapeutics, and in
the endeavor of building a business around such medicines. Ionis'
forward-looking statements also involve assumptions that, if they
never materialize or prove correct, could cause its results to
differ materially from those expressed or implied by such
forward-looking statements. Although Ionis' forward-looking
statements reflect the good faith judgment of its management, these
statements are based only on facts and factors currently known by
Ionis. As a result, you are cautioned not to rely on these
forward-looking statements. These and other risks concerning Ionis'
programs are described in additional detail in Ionis' annual report
on Form 10-K for the year ended Dec. 31,
2022, and most recent Form 10-Q, which are on file with the
SEC. Copies of these and other documents are available at
www.ionispharma.com.
Ionis Pharmaceuticals® is a registered trademark of Ionis
Pharmaceuticals, Inc.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/ionis-announces-the-appointment-of-michael-yang-to-board-of-directors-302014842.html
SOURCE Ionis Pharmaceuticals, Inc.